US equities |
AAPL $345.07 ▲+0.90% MU $904.50 ▼-2.87% TSLA $365.80 ▲+0.93% NVDA $216.47 ▼-0.35% SPCX $144.89 ▼-2.51% MSFT $540.01 ▲+0.11% AMZN $254.29 ▼-0.19% GOOGL $350.13 ▲+0.26%
FinancialContent

Protagenic Therapeutics, Inc. - Common Stock (NQ:PTIX)

0.7400 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagenic Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024 ↗
Protagenic Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024 ↗
Protagenic Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023 ↗
Protagenic Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Via ACCESSWIRE
News headline image
Earnings Scheduled For April 1, 2024 ↗
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >